TIGIT Archives -

GSK, iTeos take stock after Roche’s TIGIT setback

Phil Taylor GlaxoSmithKline, iTeos Therapeutics, Roche, TIGIT, tiragolumab 0 Comment

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT

GSK, iTeos take stock after Roche’s TIGIT setback

https://pharmaphorum.com/news/gsk-iteos-take-stock-after-roches-tigit-setback/

News/ News/ News/ Oncology/ R&D

Roche’s TIGIT ambitions take another blow

Phil Taylor immuno-oncology, Non-small cell lung cancer, Oncology, Roche, TIGIT, tiragolumab 0 Comment

Roche’s anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its

Roche’s TIGIT ambitions take another blow

https://pharmaphorum.com/news/roches-tigit-ambitions-take-another-blow/

News/ News/ Oncology

Roche hit by failure of TIGIT drug tiragolumab in lung cancer

Phil Taylor immuno-oncology, Oncology, Roche, Tecentriq, TIGIT, tiragolumab 0 Comment

Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in

Roche hit by failure of TIGIT drug tiragolumab in lung cancer

https://pharmaphorum.com/news/roche-hit-by-failure-of-tigit-drug-tiragolumab-in-lung-cancer/

News/ News/ Oncology

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

Phil Taylor BeiGene, immuno-oncology, Non-small cell lung cancer, Novartis, ociperlimab, Oncology, PD-1, TIGIT, tislelizumab 0 Comment

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

https://pharmaphorum.com/news/novartis-taps-immuno-oncology-partner-beigene-for-tigit-drug/

News/ News/ Oncology

Roche builds case for TIGIT combo in untreated lung cancer

Phil Taylor immuno-oncology, Non-small cell lung cancer, Oncology, Roche, Tecentriq, TIGIT, tiragolumab 0 Comment

Roche’s closely-watched combination of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq has shown long-term efficacy in an ongoing

Roche builds case for TIGIT combo in untreated lung cancer

https://pharmaphorum.com/news/roche-builds-case-for-tigit-combo-in-untreated-lung-cancer/

News/ News/ Oncology

Gilead foregoes buyout, but pledges $725m to Arcus’ cancer drugs

Phil Taylor Arcus Biosciences, Gilead, immuno-oncology, Oncology, partnering, R&D, TIGIT 0 Comment

Gilead Sciences has forged closer ties to its cancer drug partner Arcus Biosciences , although a licensing deal

Gilead foregoes buyout, but pledges $725m to Arcus’ cancer drugs

https://pharmaphorum.com/news/gilead-foregoes-buyout-but-pledges-725m-to-arcus-cancer-drugs/

Events/ Events/ Oncology

TIGIT Therapies 2021

Monica Mojumder Chan checkpoint inhibitor, checkpoints, TIGIT 0 Comment

Next-generation checkpoint inhibitor

TIGIT Therapies 2021

https://pharmaphorum.com/events/tigit-therapies-2021/

News/ News/ Oncology

Arcus preps more phase 3 trials for TIGIT antibody, as Gilead opt-in beckons

Phil Taylor Arcus Biosciences, Gilead Sciences, immuno-oncology, Non-small cell lung cancer, Oncology, TIGIT 0 Comment

Armed with a positive mid-stage trial readout in lung cancer, Arcus Biosciences will expand a phase 3 programme

Arcus preps more phase 3 trials for TIGIT antibody, as Gilead opt-in beckons

https://pharmaphorum.com/news/arcus-preps-more-phase-3-trials-for-tigit-antibody-as-gilead-opt-in-beckons/

News/ News/ Oncology

GSK joins anti-TIGIT push with $625m upfront iTeos deal

Phil Taylor GlaxoSmithKline, immuno-oncology, iTeos Therapeutics, Oncology, partnering, TIGIT 0 Comment

GlaxoSmithKline has staked a claim to the fast-moving category of cancer therapies targeting the TIGIT immune checkpoint, agreeing

GSK joins anti-TIGIT push with $625m upfront iTeos deal

https://pharmaphorum.com/news/gsk-joins-ant-tigit-push-with-625m-upfront-iteos-deal/

Trending

TIGIT

Login